Who are Hepsera and lamivudine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Blank maleate entecavir tablets, blank Baraclude tablets, lamivudine or entecavir, entecavir, lamivudine, Lamivudine (LAM), entecavir (BARACLUDE®).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hepsera-and-lamivudine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Hepsera and lamivudine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hepsera and lamivudine (Hepsera and lamivudine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside/nucleotide reverse transcriptase inhibitor. Area: Virology/Hepatology.

marketed Nucleoside/nucleotide reverse transcriptase inhibitor Hepatitis B virus reverse transcriptase Virology/Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Hepsera and lamivudine (Hepsera and lamivudine) — University of Washington. Hepsera (adefovir dipivoxil) and lamivudine are nucleoside/nucleotide reverse transcriptase inhibitors that block viral replication in hepatitis B by inhibiting the reverse transcriptase enzyme.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Hepsera and lamivudine TARGET	Hepsera and lamivudine	University of Washington	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor	Hepatitis B virus reverse transcriptase
Blank maleate entecavir tablets	Blank maleate entecavir tablets	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Nucleoside reverse transcriptase inhibitor	Hepatitis B virus reverse transcriptase
blank Baraclude tablets	blank Baraclude tablets	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase / HBV polymerase
lamivudine or entecavir	lamivudine or entecavir	Sun Yat-sen University	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) / Nucleotide reverse transcriptase inhibitor (NtRTI)	Hepatitis B virus reverse transcriptase; HIV reverse transcriptase
entecavir, lamivudine	entecavir, lamivudine	Asan Medical Center	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase
Lamivudine (LAM)	Lamivudine (LAM)	Hoffmann-La Roche	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase; Hepatitis B virus reverse transcriptase
entecavir (BARACLUDE®)	entecavir (BARACLUDE®)	National Taiwan University Hospital	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase / HBV polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside/nucleotide reverse transcriptase inhibitor class)

Bristol-Myers Squibb · 1 drug in this class
Nanfang Hospital, Southern Medical University · 1 drug in this class
Third Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class
University of Washington · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hepsera and lamivudine — Competitive Intelligence Brief. https://druglandscape.com/ci/hepsera-and-lamivudine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab